Article Details
Retrieved on: 2024-08-12 20:27:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses institutional investors' transactions in Ocugen Inc. (NASDAQ:OCGN) and analyzes its stock performance, where the term 'AMD' relates to Ocugen's OCU410 gene therapy targeting age-related macular degeneration. Tags like 'Financial ratios' and 'Earnings per share' reflect the stock's financial analysis.
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here